TITILOPE FASIPE to Anemia, Sickle Cell
This is a "connection" page, showing publications TITILOPE FASIPE has written about Anemia, Sickle Cell.
Connection Strength
3.793
-
Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series. Pediatr Blood Cancer. 2024 Aug; 71(8):e31061.
Score: 0.702
-
Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies. J Pediatr Hematol Oncol. 2024 07 01; 46(5):e277-e283.
Score: 0.698
-
Translational Research and Health Equity: Gene Therapies for Sickle Cell Disease as a Case Study. Ethics Hum Res. 2024 May-Jun; 46(3):34-39.
Score: 0.698
-
Still seeking balance in opioid management for acute sickle cell disease pain. Pediatr Blood Cancer. 2022 08; 69(8):e29741.
Score: 0.608
-
Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatr Blood Cancer. 2024 Oct; 71(10):e31219.
Score: 0.177
-
Multi-center retrospective study of children with sickle cell disease admitted to pediatric intensive care units in the United States. Sci Rep. 2023 04 25; 13(1):6758.
Score: 0.163
-
A Review of Sickle Cell Disease-Reply. JAMA. 2022 11 15; 328(19):1979-1980.
Score: 0.158
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
Score: 0.154
-
Regional anesthesia for sickle cell disease vaso-occlusive crisis: A single-center case series. Pediatr Blood Cancer. 2022 06; 69(6):e29695.
Score: 0.151
-
Spinal cord compression: An unusual sequela of sickle cell disease. Pediatr Blood Cancer. 2022 Nov; 69(11):e29709.
Score: 0.151
-
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. Am J Hematol. 2020 09; 95(9):E242-E244.
Score: 0.134